//fpnotebook.com/
Cancer Antigen 125
Aka: Cancer Antigen 125, CA-125, CA 125
- Indications
- Postmenopausal pelvic mass evaluation
- Ovarian Cancer serial monitoring
- Not a Screening Test for cancer (insensitive)
- May obtain baseline if Ovarian Cancer high risk
- Interpretation (CA 125 level in units/ml)
- Normal: CA-125 less than 35 (Does not exclude cancer)
- Increased
- CA-125 >35 highly correlated with cancer (epithelial Ovarian Cancer cell line)
- Used as oncology referral indication for post-menopausal women
- CA-125 >65 associated with cancer in 90% of pelvic masses
- CA-125 >200 unlikely to be due to benign condition
- Used as oncology referral indication for pre-menopausal women
- Efficacy (ranges are approximate with high values more attributed to post-menopausal patients)
- Positive Predictive Value: 35-91%
- Negative Predictive Value: 67-90%
- Test Specificity
- Pre-Menopause: 71%
- Post-Menopause: 93%
- Test Sensitivity
- Pre-Menopause: 61%
- Post-Menopause: 90%
- Stage I disease: 50%
- Advanced disease: 90%
- Causes: Increased
- Non-Cancer Causes
- Endometriosis
- Pelvic Inflammatory Disease
- Uterine Fibroids
- Pregnancy
- Menstruation
- Functional Ovarian Cyst
- Liver Cirrhosis
- Post-Menopause
- Tuberculous Peritonitis
- Pelvic Irradiation
- Malignant Causes
- Ovarian Cancer
- Liver Cancer
- Lung Cancer
- Breast Cancer
- Colon Cancer
- Pancreatic Cancer
- Endometrial Cancer
- Cervical Cancer
- References
- (2002) Obstet Gynecol 100(6):1413-6 [PubMed]
- Tuxen (1995) Cancer Treat Rev 21:215-45 [PubMed]
- Jacobs (1999) Lancet 353:1207-10 [PubMed]
- Sevinc (2007) Lancet Oncol 8(12): 1054-5 [PubMed]